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Abstract
Translesion DNA synthesis (TLS) and homologous recombination (HR) cooperate during S-phase to safeguard replication
forks integrity. Thus, the inhibition of TLS becomes a promising point of therapeutic intervention in HR-deficient cancers,
where TLS impairment might trigger synthetic lethality (SL). The main limitation to test this hypothesis is the current lack of
selective pharmacological inhibitors of TLS. Herein, we developed a miniaturized screening assay to identify inhibitors of
PCNA ubiquitylation, a key post-translational modification required for efficient TLS activation. After screening a library of
627 kinase inhibitors, we found that targeting the pro-survival kinase AKT leads to strong impairment of PCNA
ubiquitylation. Mechanistically, we found that AKT-mediated modulation of Proliferating Cell Nuclear Antigen (PCNA)
ubiquitylation after UV requires the upstream activity of DNA PKcs, without affecting PCNA ubiquitylation levels in
unperturbed cells. Moreover, we confirmed that persistent AKT inhibition blocks the recruitment of TLS polymerases to
sites of DNA damage and impairs DNA replication forks processivity after UV irradiation, leading to increased DNA
replication stress and cell death. Remarkably, when we compared the differential survival of HR-proficient vs HR-deficient
cells, we found that the combination of UV irradiation and AKT inhibition leads to robust SL induction in HR-deficient
cells. We link this phenotype to AKT ability to inhibit PCNA ubiquitylation, since the targeted knockdown of PCNA
E3-ligase (RAD18) and a non-ubiquitylable (PCNA K164R) knock-in model recapitulate the observed SL induction.
Collectively, this work identifies AKT as a novel regulator of PCNA ubiquitylation and provides the proof-of-concept of
inhibiting TLS as a therapeutic approach to selectively kill HR-deficient cells submitted to replication stress.
Introduction
The mono-ubiquitylation of Proliferating Cell Nuclear
Antigen (ubi-PCNA) steeply increases after treatment with
DNA-damaging agents that induce DNA replication fork
stalling, like hydroxyurea, methyl methanesulfonate, cis-
platin, aphidicolin, and ultraviolet (UV) irradiation [1–5].
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Ubi-PCNA, along with the specialized ubiquitin-binding
domains present in the Y-family of polymerases [6], are key
players in translesion DNA synthesis (TLS) across damaged
DNA templates [7]. Several regulatory factors of ubi-PCNA
and TLS have been identified and characterized, like p21,
REV1, USP1, and Spartan [8–10]. However, there is a lack
of selective pharmacological inhibitors of TLS that could be
used to explore the therapeutic potential of TLS inhibition.
While some efforts have been made to identify selective
inhibitors of TLS polymerases [11], there are no universal
TLS inhibitors available. Our previous work with the
PCNA-interacting domain of p21 shows that this region
blocks PCNA interaction with all the TLS polymerases
tested, including Pol eta, Pol iota, Pol kappa, and REV1,
triggering replication forks stalling and genome instability
[12]. Thus, the global and upstream interference of TLS
may have a more robust biological effect than the individual
targeting of each TLS polymerase. A central hypothesis of
this work is that a way to selectively impair TLS, without
impacting on critical housekeeping functions of PCNA,
would be to inhibit PCNA ubiquitylation. Hence, we
designed a screening focused on the modulation of PCNA
ubiquitylation. We evaluated a library of kinase inhibitors
and identified AKT as a regulator of PCNA ubiquitylation.
AKT is an iconic pro-survival kinase that controls
essential cellular functions such as growth, proliferation,
apoptosis, and metabolism [13]. In fact, even before the vast
repertoire of AKT targets were identified, multiple groups
independently demonstrated the central involvement of
AKT in promoting cell survival [14]. AKT has a well-
established anti-apoptotic function, operating both directly,
through the phosphorylation of relevant targets such as
BAD and caspases, and indirectly, through the transcrip-
tional modulation of pro-survival or pro-apoptotic genes
such as IKK/NF-κB and MDM2/p53 [15]. Herein, we
describe a new role for AKT in the regulation of PCNA
ubiquitylation and TLS. We also show that AKT inhibitors
can be used to achieve selective killing of homologous
recombination (HR)-deficient cells in a manner that depends
on their ability to inhibit PCNA ubiquitylation.
Results
Development of a miniaturized western blot-based
screening method to identify PCNA ubiquitylation
inhibitors
The mono ubiquitylated form of PCNA (ubi-PCNA) can be
detected by classical western blot using antibodies against
total PCNA. However, as the proportion of ubi-PCNA to
total PCNA is low, the detection of ubi-PCNA requires the
loading of high protein concentrations, which implies
working with samples from 24 multi-well (MW) formats or
larger (supplementary Fig. 1a). Moreover, in conditions
where the amounts of ubi-PCNA are remarkably lower (i.e.,
unperturbed or inhibited conditions), the detection of ubi-
PCNA requires even larger samples and long exposure
times with classical chemiluminescence methods. Although
such types of experiments are suitable for fundamental
research of PCNA biology, they do not provide either the
sensitivity range nor the throughput capacity required for
screening purposes. In this work, we developed a detection
method of ubi-PCNA using two monoclonal PCNA anti-
bodies. We used a novel antibody that detects ubi-PCNA in
combination with an antibody that detects total PCNA
(Fig. 1a and supplementary Figure 1b). For the detection
and quantification of each PCNA form we employ LI-COR
technology (Odyssey CLX), which provides a wide sensi-
tivity range for quantification with very low background.
This setup allowed us to perform western blots with sam-
ples obtained from a single 96-well, making it possible to
detect up to a fivefold induction of ubi-PCNA levels after
12 h of UV irradiation (Fig. 1a). The calibration of the
method was performed using nonspecific PCNA ubiquity-
lation inhibitors, such as Epoxomicin and MG-132
(Fig. 1a). These drugs inhibit the proteasome, thus caus-
ing accumulation of ubiquitylated proteins and depleting the
free ubiquitin required for normal ubiquitylation reactions
[16]. The use of a U2OS stable cell line expressing near-
infrared fluorescent protein (iRFP) and the automatic cap-
ture of brightfield images were utilized as quality controls to
monitor cell number, intra-well distribution, edge effects,
and general cytotoxicity (Fig. 1b), allowing to screen 80
compounds per 96MW plate (Fig. 1c).
Screening with a library of kinase inhibitors
With the goal of identifying novel druggable targets to
inhibit PCNA ubiquitylation, we performed a screening
using a library of 627 ATP-competitive kinase inhibitors
provided by GlaxoSmithKline (PKIS2: The Public Kinase
Inhibitor Set 2). As shown in Fig. 1b, the screening was
carried out combining each inhibitor at 1 μM with 15 J/m2
of UV irradiation. The cut-off to define a hit was a
decrease in the ratio of ubi-PCNA/total PCNA >3 stan-
dard deviations of the average of the eight UV control
samples from each screening plate. Twenty-two hits were
identified using this cut-off (Fig. 1d). The analysis of
databases such as PubChem and ChEMBL, as well as
recent publications using the PKIS library allowed us to
determine the putative target/s for the top list of hits
(supplementary table 1).
Among the 22 hits, two related AKT inhibitors
(GSK1581428A and GSK1389063A) were identified. For
simplicity, we called these compounds C11 and G8,
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respectively, due to their position on the screening plates
(supplementary Fig. 2a). Early validation experiments
confirmed that these compounds were strong inhibitors of
PCNA ubiquitylation, leading to ubi-PCNA levels in UV-
irradiated cells that were close to the non-irradiated samples
(Fig. 2a and supplementary Fig. 2b). The analysis of
phospho- and total AKT confirmed that C11 and G8 were in
fact ATP-competitive inhibitors of AKT, promoting both
the accumulation of inactive pAKT and the degradation of
total AKT (Fig. 2b), as it was previously reported for other
ATP-competitive AKT inhibitors [17, 18]. In the following
experiments, the analysis was focused on C11 due to its
remarkable activity and dose-response behavior (supple-
mentary Fig. 2b). To rule out potential off-target effects and
to assess whether the impairment of PCNA ubiquitylation
was indeed a consequence of AKT inhibition, we also
evaluated three commercially available AKT inhibitors with
different chemical backbones: MK-2206, AZD5363, and
GSK690693 (supplementary Fig. 2c). In all cases, AKT
inhibitors significantly impaired PCNA ubiquitylation
(Fig. 2c). We also confirmed that AKT activity was sub-
stantially impaired, since the downstream targets pGSK3b
and pPRAS40 abruptly decreased after the treatment with
these compounds (Fig. 2c). Among these inhibitors, MK-
2206 is particularly relevant since it has an allosteric
mechanism of action. Such activity was confirmed when
analyzing pAKT levels. It was clear that in contrast to the
ATP-competitive type of inhibitors that trigger the accu-
mulation of inactive pAKT, MK-2206 abrogated the phos-
phorylation of AKT, yet leading to similar inhibition of
GSK3β and PRAS40 phosphorylation (Fig. 2c).
To get genetic evidence to further support the involve-
ment of AKT in the regulation of PCNA ubiquitylation, we
used small interfering RNAs (siRNAs) against AKT. Con-
sistently, targeted AKT silencing recapitulated the effects of
pharmacological AKT inhibition, thus confirming AKT
participation PCNA ubiquitylation (Fig. 2d). Together, the
experiments of pharmacological AKT inhibition and siRNA
led to the conclusion that AKT promotes PCNA ubiquity-
lation after UV irradiation.

















































Fig. 1 Miniaturized western blot setup to perform a screening of
PCNA ubiquitylation inhibitors. a U2OS cells were UV irradiated (15
J/m2) and treated for 12 h with the proteasome inhibitors Epoxomicin
and MG-132. The western blot was performed with two monoclonal
antibodies to simultaneously detect total PCNA (in red) and ubi-PCNA
(in green) using a LI-COR Odyssey infrared scanner. The ratios of ubi-
PCNA/total PCNA were normalized to the highest induction of ubi-
PCNA in the non-treated (NT) UV-irradiated sample. b Three days
detailed protocol to screen for PCNA ubiquitylation inhibitors,
showing the quality controls to ensure reproducibility and robustness
of PCNA ubiquitylation induction: (i) use of an infrared scanner to
confirm the homogenous distribution of cells in the wells across
the entire plate before the addition of the screening compounds;
(ii) Automatized capture of a low magnification brightfield image at
the center of each well as a control of the general cytotoxicity of every
treatment; (iii) Lysis in benzonase w/o boiling of the samples and
direct loading of the samples to the SDS Page gel. c Layout of the 96
multi-well (MW) plates used in the screening, showing the disposition
of the non-irradiated and UV-irradiated controls. Eighty kinase inhi-
bitors per plate were evaluated and eight mini-western blots were run
in parallel with the 12 samples from each plate row. d Results of the
screening with 627 kinase inhibitors from the PKIS2 library, tested at
1 μM. The distribution of the normalized ubi-PCNA/total PCNA ratios
is shown. The dotted line represents the threshold of three standard
deviations that allowed the identification of 22 hits
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AKT promotes the induction of PCNA ubiquitylation
after UV but does not modulate PCNA
ubiquitylation in unperturbed cells
To get further insight into the signaling axis in which AKT
promotes the ubi-PCNA, we explored the inhibition of
multiple kinases that could be involved in the direct or
indirect activation of AKT in response to UV. Unsurpris-
ingly, the inhibition of the widely characterized upstream
phosphatidylinositol 3-kinase (PI3K) led to a strong inhi-
bition of PCNA ubiquitylation (Fig. 3a). This result clearly
shows that if pAKT levels are depleted, the induction of
ubi-PCNA after UV irradiation is critically impaired. PI3K
is involved in AKT activation in response to several phy-
siological ligands [19], but was not directly linked to AKT
activation after genotoxic stimuli. Therefore, we explored
the DNA damage response (DDR) kinases ATM (Ataxia
Telangiectasia Mutated), ATR (ataxia telangiectasia and
Rad3-related protein), and DNA PKcs (DNA-dependent
protein kinase catalytic subunit). Interestingly, although
both ATM and ATR inhibition did not block the induction
of PCNA ubiquitylation after UV, the inhibition of DNA
PKcs impaired PCNA ubiquitylation (Fig. 3a). DNA PKcs
inhibition also showed an additive effect when combined
with a suboptimal dose of the AKT inhibitor C11 (Fig. 3b),
thus suggesting that both kinases are part of the same cel-
lular response to promote PCNA ubiquitylation. Given that
AKT is a direct phosphorylation target of DNA PKcs in
response to UV irradiation [20], this set of findings indicate
that UV-induced DNA damage might be the trigger that
activates AKT to promote PCNA ubiquitylation. In line
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Fig. 2 AKT inhibition impairs PCNA ubiquitylation. a U2OS cells
were UV irradiated (15 J/m2) and treated for 12 h with the indicated
inhibitors at 1 μM. The western blot shows the strong PCNA ubiqui-
tylation inhibitory activity found in two structurally related hits: C11
(compound #: GSK1581428A) and G8 (compound #:
GSK1389063A). The graph in the lower panel shows the quantifica-
tion of three independent experiments. Statistical analysis was per-
formed using analysis of variance (ANOVA) with Tukey Kramer post-
test (***p ≤ 0.001). b U2OS cells were treated as in a and western
blots with specific antibodies were performed to study pAKT, total
AKT, and p-GSK3β levels. α-Tubulin was used as a loading control. c
U2OS cells were pre-treated for 12 h using 0.5 µM C11 and 5 µM of
the structurally unrelated AKT inhibitors: MK-2206 (Merck),
AZD5363 (AstraZeneca), GSK690693 (GlaxoSmithKline). After UV,
all these inhibitors were used at 20 µM and C11 was used at 1 µM. The
normalized ubi-PCNA/total PCNA ratios are shown below the PCNA
panel. pAKT, AKT, p-GSK3β, and p-PRAS40 western blots were
performed at 3 and 12 h post-treatment to confirm the AKT inhibitory
activity of each compound. d U2OS cell were transfected with two
concentrations of siRNAs. Forty-eight hours later, cells were UV
irradiated, and after 12 h, samples were processed for quantification of
PCNA ubiquitylation by western blot. A western blot for pan-AKT
was performed to confirm the siRNA-mediated knockdown. The
normalized ubi-PCNA/total PCNA ratios are shown below the PCNA
panel
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blocked the induction of PCNA ubiquitylation after UV
(including the potent AKT inhibitor C11) were able to alter
the basal levels of PCNA ubiquitylation of unperturbed
cells (Fig. 3c). This conclusion was further supported
by experiments using siRNAs against the PCNA de-
ubiquitinase USP1 [21]. Under unperturbed conditions,
knockdown of USP1 led to a substantial increase of PCNA
ubiquitylation, which was only slightly attenuated by AKT
inhibition (Fig. 3d). Therefore, we concluded that AKT is
required for efficient PCNA ubiquitylation in response to
the replication stress induced by UV irradiation.
AKT inhibition impairs the recruitment of the TLS
polymerase η to damaged DNA sites
The next important step was to confirm if the blockage of
PCNA ubiquitylation triggered by AKT inhibition suffices
to alter functional parameters of TLS. As ubi-PCNA is
required for efficient targeting of TLS polymerases to sites
of DNA damage [22], we initially studied the recruitment of
the TLS polymerase η to damaged DNA sites. To analyze
such recruitment in large cell populations, we first cloned a
hydrophilic linker (H) between Pol η and GFP, which
allowed the expression of high levels of exogenous Pol η
without apparent toxicity. Then, we generated a cell line
that stably expresses GFP-H-Pol η using lentiviral trans-
duction and puromycin selection (supplementary Fig. 3a).
With this cell line, two complementary approaches were
used to study the recruitment of Pol η to damaged sites: (1)
local UV irradiation through polycarbonate shields and (2)
total UV irradiation followed by Triton extraction. The use
of polycarbonate shields with 5 μm pores allows the irra-
diation of discrete areas within the nuclei (Fig. 4a), which
can be identified by immunofluorescence with antibodies
against one of the main types of UV-induced DNA lesions:
the cyclobutane pyrimidine dimers (CPDs). Then, within
those damaged areas we studied the efficiency of recruit-
ment of GFP-H-Pol η with or without AKT inhibition.
Although in control conditions GFP-H-Pol η recruitment
was observed in essentially every CPD-positive cell, <50%
of CPD-positive cells showed detectable GFP-H-Pol η
recruitment when AKT was inhibited (Fig. 4b). To confirm
this result, we used a method based on total UV irradiation
(Fig. 4c). In this case, the complete MW plate was irradiated
with a lower UV dose and, prior to fixation, the cells were
treated with a short pulse of Phosphate-Buffered Saline
(PBS) containing 0.1% Triton. As such, the chromatin-
bound fraction of GFP-H-Pol η remains loaded at DNA
damage areas while the soluble fraction is washed away. To
quantify the total GFP-H-Pol η fluorescence from the cells,
we developed an Image J Macro that uses DAPI (4′,6-dia-
midino-2-phenylindole) for nuclei identification and seg-
mentation. After using this macro to quantify several
images of each condition, we concluded that AKT inhibi-
tion severely impairs GFP-H-Pol η chromatin retention after
UV irradiation (Fig. 4d). Thus, AKT inhibition impairs two
functional parameters of TLS: PCNA ubiquitylation and
TLS polymerases recruitment to DNA damage sites.
The data available so far indicated that TLS is impaired
when AKT is inhibited after UV irradiation. To obtain
further evidence to consolidate this conclusion, we per-
formed DNA combing experiments to study DNA
E
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Fig. 3 AKT inhibition impairs PCNA ubiquitylation only in the con-
text of replication stress. a U2OS cells were pre-treated overnight with
the indicated kinase inhibitors: PI3K inhibitor (LY294002 50 µM),
ATR inhibitor (VE-821 1 µM), ATM inhibitor (KU-55933 1 µM),
DNA PKcs inhibitor (NU7026 20 µM), and AKT inhibitor (C11 1
µM). Cells were then submitted to UV irradiation (15 J/m2), and 12 h
in the presence of the inhibitors at the same concentrations, samples
were processed by WB for the quantification of ubi/PCNA. b U2OS
cells were treated in parallel and in combination of suboptimal doses of
the AKT inhibitor C11 (0.1 µM) and the optimal dose of the DNA
PKcs inhibitor NU7026 (20 µM). Twelve hours after UV irradiation
(15 J/m2), samples were processed by WB for the quantification of ubi/
PCNA. c U2OS cells were treated overnight with the optimal dose of
each kinase inhibitor (LY294002 50 µM, NU7026 20 µM, and C11 1
µM) followed by sample processing for WB in unperturbed conditions.
d U2OS cells were transfected with 75 nM of siRNA against USP1.
Forty-eight hours later, cells were treated with C11 1 µM and after 12
h, samples were processed for quantification of PCNA ubiquitylation
by western blot
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replication fork processivity after UV. If TLS activation is
affected after AKT inhibition, DNA replication fork pro-
cessivity should be impaired. Sequential pulses of CldU and
IdU were performed in UV-irradiated cells (Fig. 4e). The
measurement of the track length of dual color DNA fibers
allowed us to determine the relative processivity of DNA
replication forks. We observed a significant decrease in the
average speed of ongoing DNA elongation when UV-
irradiated cells were treated with AKT inhibitors (Fig. 4f).
Such impaired processivity of replication forks is in line
with the effect of AKT inhibition on ubi-PCNA levels and
on the recruitment of the TLS polymerase η to damaged
sites (Figs. 2 and 4). Together, these results indicate that
TLS activity after UV depends on AKT function, and
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Fig. 4 AKT inhibition impair translesion DNA synthesis (TLS) acti-
vation markers and replication fork processivity. a Schematic repre-
sentation of the local UV irradiation method using 5 μm micropore
filters as UV shields. b U2OS cells stably transduced with GFP-H-Pol
η were pre-treated with the AKT inhibitor C11 (0.5 μM) for 10 h and
locally UV irradiated (100 J/m2) in discrete areas of the nuclei as
indicated in (a). Immediately after irradiation, cells were re-incubated
with the AKT inhibitor for 4 h and fixed. IFs were performed to detect
cyclobutane pyrimidine dimers (CPDs), which delimitate the damaged
DNA areas. The quantification was performed by counting the CPD-
positive cells that show focal accumulation of GFP-H-Pol η. The
results of three independent experiments are shown, in which at least
200 cells/condition were analyzed. c Schematic representation of the
global UV irradiation method. d U2OS cells stably transduced with
GFP-H-Pol η were UV irradiated (40 J/m2) and incubated with C11
(0.5 μM). Four hours later, immediately prior to fixation, cells were
treated with PBS 0.1% Triton to wash out the soluble fraction of GFP-
H-Pol η. An Image J macro was developed to unbiasedly quantify the
remaining GFP-H-Pol η fraction in each experimental condition. DAPI
staining was used to segment the nuclei and at least 1000 cells/con-
dition were analyzed. The right panel shows the average of three
independent experiments. e Detailed DNA combing protocol used to
evaluate the effect of AKT inhibition on the processivity of replication
forks submitted to UV irradiation. Only bi-color fibers were measured
to ensure that only active replication replication forks were analyzed. f
DNA bi-color fibers were imaged in each condition using confocal
microscopy and were manually measured using Image J. The total
length of 200 DNA fibers/condition are shown on the right panel.
Statistical analysis shown in figures b, d and f were performed using
the T-test (**p ≤ 0.01; ***p ≤ 0.001)
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AKT inhibition induces replication-associated DNA
damage and cell death after UV
As AKT promotes TLS activation, we figured that AKT
inhibition in UV-irradiated cells should lead to increased
replication stress, DNA damage and potentially cell death.
To test this hypothesis, we first explored the phosphoryla-
tion of H2A histone family member X (γH2AX) as a broad
marker of DNA damage. Interestingly, although γH2AX did
not increased after AKT inhibition in non-irradiated cells, it
significantly increased after UV irradiation (Fig. 5a and
supplementary Fig. 3b), thus suggesting that the increased
H2AX phosphorylation in these cells could be linked to the
inhibition of TLS. Cell cycle analysis revealed that AKT
inhibition did not induced a substantial change in the profile
of non-irradiated cells (Fig. 5b), triggering only a small
increase in the sub-G1 population (Fig. 5b). As expected,
UV irradiation led to a noticeable accumulation of cells in
S-phase as a result of replication stress (Fig. 5b).
Remarkably, when UV irradiation was combined with AKT
inhibition, a substantial increase in the sub-G1 population
was observed (Fig. 5b), thus suggesting the rapid activation
of the apoptotic program in these cells. The confirmation of
cell death induction by UV irradiation combined with AKT
inhibition was performed using the cell death stain sytox
red, which showed a pronounced decrease of cell viability
(Fig. 5c). Taken together, these experiments confirmed that
AKT inhibition is more toxic in the context of UV irra-
diation, presumably due to its impact on PCNA ubiquity-
lation and TLS activation.
AKT inhibition after UV triggers synthetic lethality
(SL) in HR-deficient cells
The main goal of this work was to perform proof-of-concept
experiments to test the hypothesis that inhibiting PCNA
ubiquitylation should become increasingly toxic in cellular
backgrounds with deficient HR repair. To test this, we used
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Fig. 5 AKT inhibition triggers replication stress-associated DNA
damage and cell death after UV irradiation. a U2OS cells were UV
irradiated (15 J/m2) and 24 h later, cells were fixed and γH2AX
immunostaining was performed. An Image J macro was developed to
quantify only the nuclear γH2AX signal using DAPI for segmentation.
Two doses of the AKT inhibitor C11 were used. The right panel shows
the average of two independent experiments were at least 100 cells/
condition were analyzed. Statistical analysis was performed using
analysis of variance (ANOVA) with Tukey Kramer post-test (*p ≤
0.05). b U2OS cells were UV irradiated (15 J/m2) and treated with C11
(0.5 µM). Twenty-four hours later, cells were processed for cell cycle
analysis by flow cytometry using propidium iodide (PI). Cell cycle
analysis was performed using Flowjo Tree Star, Inc. software. The
right panel shows the determination of the relative % of each cell cycle
phase, including the apoptotic sub-G1 population. c U2OS cells were
UV irradiated (15 J/m2) and treated with the AKT inhibitor C11 (0.5
µM). Twenty-four hours later, cells were stained using the dead cells
stain Sytox red and cells were immediately processed by flow cyto-
metry. The % of live and dead cells was determined for each condition
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a method developed in our lab, in which HR-proficient and
HR-deficient cells are co-cultured in the same well, fol-
lowed by the quantification of the percentage of cells of
each population that survive the treatment (Fig. 6a). In this
experimental setting, HR deficiency in isogenic genetic
backgrounds is artificially induced by lentiviral transduction
of short hairpin RNAs (shRNAs) against BRCA1. The
downregulation of BRCA1 was assessed by western blot
and the inhibition of HR was confirmed using the direct
repeats method from Maria Jasin's Lab (supplementary
Fig. 4a and b). As HR-proficient (shSCR) and HR-deficient
cells (shBRCA1) are tagged with different fluorescent
proteins, the relative viability of both cell populations is
determined at the end of the experiment by cell counting
using automated flow cytometry (Fig. 6a). This assay allows
to discriminate if a given treatment (or a combinations of
Day 1 Day 2
 UV irradiation
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treatments) is equally or selectively toxic for a given genetic
background (Fig. 6a). As a positive control of SL induction,
we used Olaparib (Fig. 6b), a well-characterized Poly
(ADP-ribose) Polymerase (PARP) inhibitor that induce SL
in HR-deficient cells [23]. Remarkably, when combining
UV irradiation and AKT inhibition, a strong induction of
SL was observed in a UV dose-dependent manner using
C11 and other AKT inhibitors (Fig. 6c). To exclude
potential artifacts derived from the co-culture of BRCA1-
proficient and -deficient populations, we also performed a
clonogenic assay using single-cell cultures. We observed a
decreased clonogenic potential in C11-treated HR-deficient
cells when compared with C11-treated HR-proficient cells
(Fig. 6d).
To validate this SL phenotype in different genetic
backgrounds, we performed survival experiments with
multiple pairs of isogenic and non-isogenic cell lines (HR
proficient vs HR deficient). We used a pair of triple-
negative breast cancer cell lines (MDA-MB 231-BRCA1wt
vs MDA-MB 436-BRCA1KO), a set of wt mouse
embryonic fibroblast (MEF) (shSCR vs shBRCA1), a
hamster BRCA2 KO cell line with its reconstituted coun-
terpart (V-C8 vs VC#13) and a pair HCT116 cells (shSCR
vs shBRCA2). A sine qua non to use these cell lines was the
selective sensitivity to Olaparib in the BRCA-deficient
counterpart of each pair (supplementary Fig. 4c). In all cell
lines, AKT inhibition impaired PCNA ubiquitylation
induction (Fig. 6e) and triggered SL in the HR-deficient
counterpart of each cell pair after UV (optimal SL doses are
depicted in Fig. 6f and full dose-response panels in sup-
plementary Fig. 4c).
Taken together, these results allowed us to conclude that
AKT inhibition in the context of UV irradiation triggers SL
in HR-deficient cells.
Direct inhibition of PCNA ubiquitylation is synthetic
lethal in HR-deficient cells submitted to replication
stress
Although our data clearly showed that AKT inhibition
impairs PCNA ubiquitylation (Fig. 2) and triggers SL in
HR-deficient backgrounds after UV (Fig. 6), a direct caus-
ality between ubi-PCNA decrease and SL induction cannot
to be claimed given the multiple roles of AKT in cell sur-
vival pathways [13]. Hence, we used additional experi-
mental models to study the contribution of PCNA
ubiquitylation to the cell survival of UV-irradiated HR-
deficient cells. Our initial approach was to downregulate
RAD18, the E3-ligase in charge of PCNA mono-
ubiquitylation [24]. We used a lentiviral shRNA transduc-
tion protocol to knockdown RAD18. We tested four dif-
ferent shRNA sequences and selected two that promoted
strong RAD18 downregulation and that severely impaired
PCNA ubiquitylation after UV (Fig. 7a, b). Then, we
adapted our SL induction assay to assess the impact of
RAD18 knockdown in the differential survival linked to UV
irradiation and HR proficiency (Fig. 7c). Increased sensi-
tivity to UV in shRAD18-transduced cells was observed
exclusively in the HR-deficient cell line, but not in the
isogenic HR-proficient cell line (Fig. 7d and supplementary
Fig. 4D). Although this result indicates that the inhibition of
PCNA ubiquitylation could be triggering SL in HR-
deficient cells exposed to UV, the fact that RAD18 might
be ubiquitylating other HR-relevant targets complicates the
drawing of a simple cause-effect conclusion. Therefore, we
also used a knock-in MEF model, where wt PCNA was
replaced by a non-ubiquitylable version harboring the point
Fig. 6 AKT inhibition is synthetic lethal with the homologous
recombination (HR) deficiency induced by BRCA1 knockdown. a
Experimental layout and detailed protocol used to assess synthetic
lethality (SL) induction using a co-culture method of HR+ and HR–
isogenic HCT116p21-/- cell lines, generated by lentiviral transduction of
shRNAs against BRCA1. Each cell line co-expresses a different
fluorescent protein: shSCR (CFP) and shBRCA1 (iRFP). Equal
numbers of both isogenic cells were then plated in triplicates in 96
MW plates and combinations of increasing UV doses with AKT
inhibitors were performed. Six days post-treatment, the co-cultured
population was counted and categorized by the differential expression
of fluorescent proteins using automated flow cytometry with an
autosampler. The remaining % of each cell population was determined
and the ratio of HR–/HR+ cells was calculated. The relative survival
of each cell population in comparison with the untreated controls was
determined to calculate SL induction by the different treatments. b
Positive control to calibrate the robustness of the SL induction assay at
6 days using the PARP inhibitor Olaparib (0.1 μM), which is selec-
tively toxic against the HR– population. c Determination of SL
induction using HR+ (shSCR) and HR– (shBRCA1) isogenic
HCT116p21-/- cells in a dose-response UV irradiation curve combined
with three AKT inhibitors after 6 days of treatment: C11 (0.1 µM),
MK-2206 (1 µM) and AZD5363 (1 µM). Statistical analysis shown in
figures b and c was performed using analysis of variance (ANOVA)
(*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001). d Clonogenic experiments
comparing HCT116p21-/- shSCR vs. shBRCA1 cells treated with the
combination of AKT inhibition (C11 0.1 µM) and UV irradiation.
Duplicates of each treatment are displayed. Seven hundred fifty cells
were plated in a 96MW format and after 6 days the survival fraction
was stained with crystal violet. e Control WBs confirming the efficient
impairment of PCNA ubiquitylation after UV triggered by AKT
inhibition for every cell line used to validate the induction of SL. In the
case of mouse and hamster cells (MEF and V-C8), the detection of
PCNA ubiquitylation was performed using the total PCNA antibody
(PC-10) because the Ubiquityl-PCNA antibody (D5C7P) only reacts
with human samples. f Determination of SL induction using HR+ and
HR– cells (BRCA1 or BRCA2 deficient) at the optimal UV irradiation
dose in combination with the AKT inhibitor C11 (1 µM). A pair of
triple-negative breast cancer cell lines (MDA-MB 231-BRCA1wt vs
MDA-MB 436-BRCA1KO), a set of wt mouse embryonic fibroblast
(MEF) (shSCR vs shBRCA1), a hamster BRCA2 KO cell line with its
reconstituted counterpart (V-C8 vs VC#13) and a pair of HCT116p21-/-
cells (shSCR vs shBRCA2) were used. Statistical analysis shown in
panels b, c, and f was performed using analysis of variance (ANOVA)
(*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)
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mutation K164R [25]. We first confirmed that PCNAK164R
cells do not display induction of PCNA ubiquitylation after
UV (Fig. 7e). Later on, we performed survival experiments
in which BRCA1 was downregulated by lentiviral shRNAs
in both PCNAWT and PCNAK164R MEFs. Remarkably, a
strong SL induction was observed in BRCA1-deficient
PCNAK164R cells (Fig. 7f). These results consolidate our
findings that ubi-PCNA impairment leads to SL induction in
HR-deficient cells, and demonstrates that a targeted block-
age of PCNA ubiquitylation by different experimental
approaches suffices to induce SL. Although these data put
forward a novel therapeutic strategy to selectively kill HR-
deficient cells, an obvious limitation from these experiments
is that UV irradiation cannot be used as a sensitizer in a
clinical setup. Thus, we decided to evaluate cisplatin, a
well-characterized replication stress inducer that requires
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active TLS for DNA damage processing [26]. Strikingly,
the HR-deficient counterpart of both shRAD18-transduced
cells and PCNAK164R MEF displayed increased sensitivity
to cisplatin (Figs. 7g, h, respectively). Collectively, these
results unveil the potential of inhibiting PCNA ubiquityla-
tion as a therapeutic strategy to sensitize HR-deficient cells
to treatments that induce replication stress and activation of
TLS.
Discussion
A new function for AKT in the promotion of cell
survival: the regulation of DNA damage tolerance
A central regulatory affair for cell survival is to balance
DNA repair and apoptosis induction in response to DNA
damage load. As DNA damage is an unceasing threat
arising from both endogenous and exogenous sources [27],
DNA repair pathways are unable to cope with every single
DNA damage event in real time, in particular at sensitive
points of the cell cycle such as S-phase [28]. Hence, a series
of specialized mechanisms have evolved to deal with
unrepaired DNA damage in S-phase to promote cell survi-
val and to increase the time-frame for DNA repair
mechanisms to attend the damage, which are collectively
referred as DNA damage tolerance pathways [22, 29]. The
most well-characterized tolerance pathways are template
switch and TLS, two related mechanisms to deal with
damaged DNA in S-phase, which share a common player:
ubiquitylated PCNA [30]. Although TLS involves mono
ubi-PCNA and template switch involves poly ubi-PCNA,
the poly-ubi-PCNA requires the initial mono-ubiquitylation
at the same K164 residue [30]. Thus, the inhibition of
PCNA mono-ubiquitylation also implies the inhibition of
PCNA poly-ubiquitylation, and the potential impairment of
both DNA damage tolerance pathways.
The findings of this article unveil a novel pro-survival
role for AKT, the modulation of PCNA ubiquitylation. Our
data not only consistently demonstrate such new role by
pharmacological and siRNA-mediated inhibition of AKT
(Fig. 2 and supplementary Fig. 2), but also prove that
blocking PCNA ubiquitylation through AKT inhibition
modifies functional parameters of TLS, such as TLS poly-
merases recruitment to damage sites, replication forks pro-
cessivity, replication stress induction, and cell survival after
UV irradiation (Figs. 4 and 5). Regarding the upstream
players of AKT activation in the context of replication
stress, there is compelling evidence suggesting that the
master DDR kinase DNA PKcs regulates AKT through
direct phosphorylation at Ser473 in response to ionizing
DNA damage [31–33] and UV irradiation [20]. Our results
indicate that DNA PKcs is the DDR kinase that might be
coordinating AKT activation to promote PCNA ubiquity-
lation in response to UV. Given the results with the inhi-
bitor LY294002 (Fig. 3a), we cannot exclude that PI3K also
participates in the same or a parallel pathway that DNA
PKcs in response to replication stress. Nonetheless, a clear
conclusion from our results is that the basal levels of PCNA
ubiquitylation are not affected by any of these kinases,
including AKT itself (Fig. 3c). Thus, it is feasible that a
replication stress-triggered axis involving DNA PKcs and
AKT is activated to promote PCNA ubiquitylation and TLS
when damaged DNA accumulate in cells.
An important question that remains open for future stu-
dies is the identity of the downstream AKT targets
responsible of promoting PCNA ubiquitylation, and whe-
ther this occurs directly through the phosphorylation of
relevant substrates by AKT or if it requires a more complex
signaling cascade. Potential starting points for this research
are some of the kinases identified as hits in the screening
performed herein, such as IKK and p38 (supplementary
Fig. 7 Abrogation of PCNA ubiquitylation triggers synthetic lethality
in homologous recombination (HR)-deficient cells submitted to
replication stress. a HCT116p21−/− cells were transduced with four
different shRNAs against RAD18 at increasing multiplicities of
infection (MOI). Seventy-two hours later, cells were processed for
western blot to detect RAD18. b HCT116p21-/- cells were transduced
with the most efficient RAD18 shRNAS (#1 and #4). After 72 h, cells
were UV irradiated (15 J/m2) and the induction of PCNA ubiquityla-
tion was analyzed by western blot 12 h later. c Detailed protocol used
to assess SL induction after RAD18 knockdown. Cells were plated in
6MW plates and transduced with lentiviral shRNAs #1 or #4. Forty-
eight hours later, cells were re-plated into a 96MW format. Twenty-
four hours later, cells were UV irradiated. Six days post UV irradia-
tion, the determination of SL induction using HR+ and HR– cells was
performed by calculating the relative survival of the cells transduced
with the shRNA against RAD18 in comparison with the non-
transduced cells. Such differential analysis was possible by gating
the transduced population due to the concomitant expression of GFP
with the shRNAs. d HR+ and HR- cells were transduced with shRNA
#1 using the protocol detailed in (c). The relative survival of the
transduced population was calculated using the non-irradiated popu-
lation as control. A dose-response UV curve was performed, and
samples were processed using eight experimental replicates. e PCNA
wt and PCNA K164R mouse embryonic fibroblasts (MEFs) were UV
irradiated (40 J/m2). Twelve hours after UV irradiation, samples were
processed for WB and ubi-PCNA induction was assessed using a
monoclonal antibody that detects mouse PCNA. f PCNA wt and
PCNA K164R MEFs were transduced with shRNAs against murine
BRCA1. Each set of cells were UV irradiated following a dose-
response curve with or without treatment with the AKT inhibitor C11.
After 6 days, the relative survival of each cell population was deter-
mined using automated flow cytometry. g HR+ and HR– cell pairs
were treated with cisplatin and after 1 h the culture media was
replaced. The relative survival of the different HR– vs HR+ pairs was
assessed 6 days later. h PCNA wt and PCNA K164R MEFs were
treated with cisplatin and after 1 h the culture media was replaced. The
relative survival of the different HR– vs HR+ pairs was assessed
6 days later. Statistical analysis shown in panels d, f, g, and h
was performed using analysis of variance (ANOVA) (*p ≤ 0.05;
**p ≤ 0.01; ***p ≤ 0.001)
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table 1). Nonetheless, omics approaches such as RNAseq or
phosphor-proteomics comparing UV-irradiated ± AKT
inhibitors will most likely be required to tackle this issue in
a more comprehensive manner. It will also be important to
study in more detail the TLS regulatory proteins RAD18
and REV1 since two lines of evidence suggest that an axis
involving AKT/REV1/RAD18 could modulate PCNA ubi-
quitylation. First, a recent report showed that increased
REV1 levels boost PCNA ubiquitylation after UV irradia-
tion through the direct interaction with RAD18 [34]. Sec-
ond, the deletion mutant of yeast AKT homolog Sch9
displays reduced levels of REV1 and impaired TLS [35].
In this article, we establish for the first time a connection
between AKT and DNA damage tolerance through TLS
activation. Interestingly, AKT has also been linked to the
modulation of DNA repair pathways to promote cell sur-
vival yet compromising genome stability, which can be
considered as additional DNA damage tolerance strategies.
One clear example is the modulation of mismatch repair
(MMR) by AKT, through the control of the stability and
localization of the MMR protein hPMS2 [36]. As the
induction of apoptosis by base adducts like O6MeG
requires active MMR, the attenuation of MMR by AKT
might promote cell survival in this context, yet increasing
the chances of acquiring mutations [37]. Another example
of the activation of error-prone DNA repair mediated by
AKT to promote cell survival is the stimulation of non-
homologous end joining, NHEJ, by collaborating with
DNA PKcs (reviewed in [37]). Hence, our work builds up
on an emerging role for AKT and DNA PKcs in DNA
damage tolerance, which will be of great importance to
understand the mechanisms that govern the choice between
cell survival and cell death triggered in response to DNA
damage.
TLS inhibition as a novel therapeutic strategy
against HR-deficient cancers
Reports by many different groups showed that PCNA ubi-
quitylation and ubiquitin-binding domains on TLS poly-
merases are less critical for cell survival in mammalian cells
than in yeast. On the one hand, it was reported by different
groups that to boost the sensitivity associated with TLS
inhibition in different cellular models, a concomitant inhi-
bition of checkpoint activation by caffeine treatment is
required [38, 39], thus showing that the intricated DDR
network in mammals is able to buffer TLS impairment. On
the other hand, critical evidence of the relevance of PCNA
ubiquitylation came with the generation of a mammalian
knock-in model of non-ubiquitylable PCNA [25, 40]. The
PCNA K164R MEFs obtained showed increased—yet
moderate—UV sensitivity when compared with wt MEFs,
in particular at low UV doses [40]. Such mild UV-triggered
sensitivity observed in mammalian cells in comparison with
the extreme phenotype observed in yeast [1], along with the
central housekeeping roles of PCNA in DNA replication
[41, 42], discouraged the field from further exploring the
therapeutic potential of targeting PCNA ubiquitylation.
However, the possibility that some genetic backgrounds
could depict enhanced sensitivity to TLS inhibition
remained almost completely unexplored. In such context,
the driving hypothesis of this work was that the UV sen-
sitivity associated with PCNA ubiquitylation inhibition
could become much stronger in DNA repair-deficient con-
texts. In particular, we were interested in exploring HR-
deficient contexts, due to the complementary and compen-
satory role that HR plays with TLS during replication stress
[28]. Moreover, recent reports revealed that HR deficiency
is a much more widely spread feature of human cancers
than anticipated [23, 43], and therefore it is a niche of cri-
tical importance for drug discovery and for the design of
novel therapeutic strategies.
The rationale we followed was that the sole inhibition of
TLS would be insufficient to trigger substantial lethality of
HR-deficient cells, and therefore should be combined with
replication stress inducers such as UV or cisplatin. When
we inhibited PCNA ubiquitylation by AKT inhibition,
RAD18 knockdown or using a knock-in model of non-
ubiquitylable PCNA, we observed SL induction in BRCA-
deficient cells (Figs. 6 and 7), thus indicating that the
targeted inhibition of DNA damage tolerance pathways is
selectively toxic when cells are deficient in HR. These
results are promising and put forward the use of pharma-
cological TLS inhibitors as sensitizers of widely used
replication poisons such as cisplatin, which are currently the
standard of care for HR-deficient cancers [23]. Moreover,
these findings also suggest that PCNA ubiquitylation inhi-
bitors would be of therapeutic utility to counteract the
resistance to cisplatin, which has been linked in the past to
the overexpression of TLS polymerases [44–46]. Although
some currents efforts to inhibit TLS by targeting TLS
polymerases have been reported [11], we believe that
inhibiting PCNA ubiquitylation should have a more robust
effect on TLS inhibition, as it would have a universal effect
on the recruitment of TLS polymerases. This notion is
supported by our previous work with the TLS inhibitor p21,
which is able to block the recruitment of all TLS poly-
merases to DNA damage sites, thus impacting on TLS
efficiency [12, 47]. Taken together, our data put forward a
novel model of SL induction with great therapeutic potential
against HR-deficient cancer cells, where TLS inhibition can
act as a strong sensitizer for the specific killing of cells
submitted to replication stress. Excitingly, in this context
our findings also propose a new therapeutic utility for AKT
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inhibitors that are currently in clinical trials [48, 49], which
might be used in combination with replication stress indu-
cers in patient cohorts with known HR deficiencies.
Materials and methods
DNA constructs, shRNA, and siRNA
The parental GFP-Polη plasmid was a gift from Dr. Alan
Lehmann. GFP-H-Polη was obtained by cloning a flexible
hydrophilic linker between Polη and GFP using XhoI
restriction site [50]. For stable expression, GFP-H-Polη was
cloned into pLenti (w175-1) vector through BamHI and
XbaI restriction sites. shRAD18 lentiviral vectors were
purchased from Origene (#1: TL302132C; #2: TL302132B;
#3: TL302132D; #4: TL302132A). shBRCA1
(TRCN0000010305, Sigma-Aldrich) was cloned into
pLKO.1-TRC vector through EcoRI and AgeI restriction
sites; and shSCR-pLKO.1 was purchase from Addgene
(ID#1864). The siRNA duplexes used (Cell Signaling
Technology) were: siSCR (control) 6568S and siAKT
6211S.
Antibodies
Primary antibodies used were: α-ubiquityl-PCNA (D5C7P;
Cat# 13439), α-PCNA (PC-10; Cat# 2586), α-pan-Akt
(Cat# 4691), α-phospho-Akt (Ser473; Cat# 9271), α-phos-
pho-GSK3B (Ser9; Cat# 9336), α-phospho-PRAS40
(Thr246; Cat# 2997), α-RAD18 (Cat# 9040) and α-SMC-1
(Cat# 4802) from Cell Signaling Technology; α-BRCA1
(Ab-1) from Oncogene Research; α-PCNA (PC-10, Cat# sc-
56) from SCBT; α-γH2AX (Cat# 05-636-1) from Millipore;
α-CPD (Cat# NMDND001) from Cosmo Bio; α-Tubulin
(Cat# T9026) from Sigma-Aldrich. Secondary antibodies
used were: α-mouse Alexa Fluor 594 from Jackson
ImmunoResearch; goat α-mouse IRDye 680RD (Cat# P/N
925-68070) and goat α-rabbit IRDye 800CW (Cat# P/N
925-32211) from LI-COR Biosciences. Nuclei were stained
with DAPI (Cat# D9542) from Sigma-Aldrich.
Cell culture, transfections, and UV irradiation
U2OS, MDA-MB 231, and 436 cell lines were acquired
from ATCC. U2OS cells stably expressing DR-GFP were
kindly provided by M. Jasin [51]. PCNA wt and PCNA
K164R MEF cell lines were previously described by H.
Jacobs [25]. HCT116p21-/- were kindly provided by B.
Vogelstein. V-C8 cell lines were supplied by B. Lopez.
U2OS cell lines were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Thermo Fisher Scientific) sup-
plemented with 5% fetal bovine serum (FBS; GIBCO).
Remaining cell lines were cultured in DMEM supplemented
with 10% FBS. HEK293T cells were transfected to obtain
virus particles using JetPrime (Polyplus-transfection)
according to manufacturer’s instructions. siRNAs (100–200
nM) were transfected into cells at 40% confluence, using
JetPrime (Polyplus-transfection). Local and global UV
irradiation was performed as previously described [52]. All
the cell lines used in this work were negative for myco-
plasma contamination.
Protein analysis
For direct western blot analysis, samples were lysed in
commercial Laemmli buffer (BioRad) with reducing agent
2-mercaptoethanol. The detection and quantification were
performed with Odyssey Clx System (LI-COR Biosciences)
through the Image Studio Software.
Immunofluorescence and image analysis
Immunofluorescence and CPD staining were performed as
described previously [52]. For GFP-H-Pol η foci detection,
cells were pre-extracted with 0.1% Triton for 5 min on ice
prior fixation. This method allows detection of only well-
assembled foci. Images were captured using an optical
microscope equipped with a motorized stage (Leica DMI 8).
To quantify the total GFP or γH2AX fluorescence, an Image
J Macro was developed using DAPI for nuclei identification
and segmentation.
Cell cycle and cell death analysis
For cycle analysis, cells were prepared as described pre-
viously [53]. SYTOX Red (Thermo Fisher Scientific) was
used for dead cell staining according as previously descri-
bed [54]. Stained samples were subjected to fluorescence-
activated cell sorting (FACS) (Attune NxT, Thermo Fisher
Scientific) and data were analyzed using FlowJo software
(FlowJo LLC). When indicated, the profiles shown were
obtained by gating the positive cells by dual-channel FACS
analysis.
Preparation and immunolabelling of DNA combing
DNA combing was performed according to our previously
described protocol [12] with modifications. Briefly, cells
were irradiated with 15 J/m2 UVC and treated or not with
C11 (0.5 µM). After 16 h of treatment, cells were pulse
labeled with CldU (20 mM) for 10 min, washed twice, and
incubated with IdU (200 mM) for additional 30 min (200
mM). DNA fibers were visualized using a Zeiss Axioplan
confocal microscope. Images were analyzed using Zeiss
LSM Image Browser software. Only bi-colored fibers were
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quantified to ensure that only active replication forks, but
neither terminations nor recently fired origins, were
analyzed.
Clonogenic assay
Seven hundred fifty HCT116p21-/- shSCR or shBRCA1 cells
were plated in a 96MW format. Cells were treated with a
combination of AKT inhibition (C11 0.1 µM) and UV
irradiation and after 6 days the survival fraction was stained
with crystal violet.
HR analysis
We used an HR assay generated previously in U2OS cells
containing an integrated HR reporter substrate DR-GFP
[51] with some modifications described previously [53].
Statistical analysis
All experiments were performed by duplicate or triplicate.
Graphs and statistical analysis were performed using
GraphPad Prism 5.0 (GraphPad Software), applying two-
sided Student’s t-test and analysis of variance (ANOVA)
test as appropriate. Bars represent the mean value ± s.d.
Other calculations were performed using Microsoft Excel
2003.
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